TOPLINE

An analysis of national prescription data showed that oral semaglutide for weight management topped 100,000 new prescriptions per month within 2 months of its January 2026 launch, with notably higher early uptake than that of injectable tirzepatide or semaglutide. Injectable semaglutide prescriptions did not decline, while the combined number of oral and injectable semaglutide prescriptions increased, suggesting that the pill may have expanded the treated population rather than simply replacing injections.

METHODOLOGY

• Needle aversion, cost, and access continue to pose challenges to the use of GLP-1 injectables for weight loss, and a daily semaglutide pill launched in January 2026 could broaden adoption.
• To see how quickly the pill caught on and whether it added to the total number of people treated with incretin-based drugs, researchers used national data on new prescriptions filled monthly at US retail pharmacies from July 2020 through June 2026. They focused on branded weight-loss drugs: a daily semaglutide pill, injectable semaglutide, and injectable tirzepatide.
• Each drug's launch trajectory and the time taken to reach 100,000 monthly prescriptions were compared.
• To judge whether the pill added to the market or replaced injectable treatments, the team tracked oral and injectable semaglutide prescriptions alongside combined prescription volumes for semaglutide and tirzepatide.
• To check for spillover effects, the researchers also analyzed prescriptions for oral semaglutide, injectable semaglutide, and injectable tirzepatide products marketed for type 2 diabetes.

TAKEAWAY

• Within 2 months of launch, the oral semaglutide pill surpassed 100,000 monthly new prescriptions. Tirzepatide took 4 months to reach that mark, and injectable semaglutide took 20 months.
• Early prescriptions for the pill climbed about 4.4 times more steeply than those for injectable tirzepatide and 7.4 times more steeply than those for injectable semaglutide.
• Injectable semaglutide prescriptions did not decline after the pill's introduction. Total semaglutide prescriptions for weight loss rose, with the pill accounting for much of the increase. By June 2026, the total number of semaglutide prescriptions was close to, but still below, the number of tirzepatide prescriptions.
• Prescriptions for oral semaglutide used for type 2 diabetes remained roughly stable after the weight-loss pill launched.

IN PRACTICE

"Oral formulations appear to reach additional patients," the authors wrote.

SOURCE

The study was led by Yara Jelwan, MD, MPH, Johns Hopkins Ciccarone Center for Cardiovascular Disease Prevention in Baltimore. It was published online on October 12 in Annals of Internal Medicine.

LIMITATIONS

The data were aggregated, so individual patients and switching between drugs could not be tracked. Off-label use could not be excluded. The dataset also lacked details on coverage, denied claims, and cash payments, and compounded semaglutide and tirzepatide were not captured. 

DISCLOSURES

No specific funding was reported. One author reported consulting for and receiving grants from pharmaceutical companies, including the manufacturer of oral semaglutide.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.